Research Topics
| CRAIG LEE SLINGLUFFSummaryAffiliation: University of Virginia Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed scheduleCraig L Slingluff
Department of Surgery, Human Immune Therapy Center, University of Virginia Health System, Charlottesville, VA 22908, USA
J Clin Oncol 22:4474-85. 2004....- Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant settingCraig L Slingluff
Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
Clin Cancer Res 13:6386-95. 2007..Because melanomas commonly evade immune recognition by selective antigen loss, optimization of melanoma vaccines may require development of more complex multipeptide vaccines... 
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic functionWalter C Olson
Human Immune Therapy Center, University of Virginia, Charlottesville, VA, USA
J Transl Med 9:26. 2011..The effect of temperature during storage and shipment of peripheral blood on subsequent processing, recovery, and function of lymphocytes is understudied and represents the focus of this study...- A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"Lisa H Butterfield
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
J Transl Med 6:81. 2008..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document... - Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysisJochen T Schaefer
Human Immune Therapy Center, University of Virginia, Charlottesville, VA, USA
J Transl Med 8:79. 2010..We hypothesized that a vaccine in incomplete Freund's adjuvant (IFA) would increase dermal Th1 and Tc1-lymphocytes and mature DCs, but that repeated vaccination may increase regulatory cells... - The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccinesDonna H Deacon
Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
BMC Cancer 8:360. 2008..We have, therefore, investigated ultraviolet (UV)-irradiation as a possible adjunct to, or replacement for gamma-irradiation... - Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigensCraig L Slingluff
Department of Surgery Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
J Clin Oncol 26:4973-80. 2008..Source proteins for these peptides include MAGE proteins, MART-1/MelanA, gp100, and tyrosinase... - The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptidesRebecca C Harris
Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
J Immunother 35:78-88. 2012..Further study of the physiology of the vaccine site microenvironment promises to identify opportunities for enhancing cancer vaccine efficacy by modulating immune activation and regulation at the site of vaccination... - Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cellsCraig L Slingluff
Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, 22908, USA
J Clin Oncol 21:4016-26. 2003..To determine clinical and immunologic responses to a multipeptide melanoma vaccine regimen, a randomized phase II trial was performed... - Peptide and dendritic cell vaccinesCraig L Slingluff
Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
Clin Cancer Res 12:2342s-2345s. 2006.... - Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesCraig L Slingluff
Department of Surgery, Division of Surgical Oncology, University of Virginia, Charlottesville, VA 22908, USA
Ann Surg Oncol 15:3538-49. 2008.... - Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomesC L Slingluff
Department of Surgery, University of Virginia, Charlottesville, 22908, USA
Clin Cancer Res 7:3012-24. 2001..Although this Phase I study was not intended to evaluate clinical benefit, the excellent survival of patients on this protocol suggests the possibility of a benefit that should be assessed in future studies... - Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccinesCraig L Slingluff
Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, VA 22908, USA
J Immunother 33:630-8. 2010..Despite the necessarily retrospective nature of the analysis and limitations of multiple comparisons, our summary data support the use of IFA-VG as an adjuvant with multipeptide vaccines in melanoma patients... - Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineCraig L Slingluff
Department of Surgery, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
J Clin Oncol 29:2924-32. 2011.... - The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Craig L Slingluff
Human Immune Therapy Center, University of Virginia, Charlottesville, USA
Cancer J 17:343-50. 2011..To apply these new approaches optimally, it will be critical to study their effects in the context of defined antigens, for which peptide vaccines are optimal... - gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cellsL S Kierstead
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
Br J Cancer 85:1738-45. 2001..Based on these data, these epitopes may serve as potent vaccine components to promote clinically-relevant Th1-type CD4+ T cell effector function in situ... - Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patientsG V Yamshchikov
Division of Surgical Oncology, Department of Surgery, University of Virginia HSC, Charlottesville, VA 22908, USA
Int J Cancer 92:703-11. 2001..This combination of an immunogenic vaccine strategy with a sensitive analysis of CTL responses demonstrates the potential for inducing and detecting anti-tumor immune responses in the majority of melanoma patients... - Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigensC L Slingluff
Department of Surgery, University of Virginia, Charlottesville 22906, USA
Cancer Immunol Immunother 48:661-72. 2000.... - Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapyM M Moore
Division of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia 22908 0709, USA
Ann Surg 231:877-82. 2000.... - Patient preferences for adjuvant interferon alfa-2b treatmentK L Kilbridge
Department of Health Evaluation Sciences, University of Virginia Health System, Charlottesville, VA 22908 0821, USA
J Clin Oncol 19:812-23. 2001..Utilities are measures of preference for a particular health state on a scale of 0 (death) to 1 (perfect health)... - Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluationsG Yamshchikov
Department of Surgery, University of Virginia Health Sciences Center and Cancer Center, Charlottesville 22908, USA
Clin Cancer Res 7:909s-916s. 2001..These data provide an estimate of the level of CTL response that may be associated with protection from tumor recurrence... - Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicityLee W Thompson
Department of Surgery, University of Virginia, Charlottesville 22908, USA
J Immunother (1997) 27:177-83. 2004..These findings suggest general strategies for enhancing the antigenicity of other peptides containing similar amino acids in their sequence... - The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopesSara J Adair
Department of Surgery and the Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
J Immunother 31:7-17. 2008..These results indicate that TAG-derived peptides may be good components of a therapeutic vaccine designed to target melanoma and a variety of epithelial cell-derived malignancies... 
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancerKimberly A Chianese-Bullock
Department of Surgery, Division of Surgical Oncology, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
J Immunother 31:420-30. 2008....- Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excisionHeather L Evans
Department of Surgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA
Ann Surg Oncol 10:416-25. 2003..Patients have traditionally been considered candidates for sentinel node biopsy (SNBx) only at the time of wide local excision (WLE). We hypothesized that patients with prior WLE may also be staged accurately with SNBx... - MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinomaTomohide Tatsumi
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Clin Cancer Res 9:947-54. 2003..These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma... - Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature reviewLiana Abramova
Department of Surgery, University of Virginia Health Science Center, Charlottesville, Virginia 22906, USA
Ann Surg Oncol 9:840-6. 2002..CONCLUSIONS: This experience, plus reports of a small number of patients from three similar studies, supports the impression that sentinel lymph node biopsy is feasible for vulvar and vaginal melanoma... - Problems in the interpretation of apparent "radial growth phase" malignant melanomas that metastasizeLiana Abramova
Department of Pathology, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
J Cutan Pathol 29:407-14. 2002..It is possible that strictly defined RGP melanomas may metastasize in very rare cases. Our observations also suggest that metastatic potential is a function of numerous factors, and may not be evaluable on morphological grounds alone... - Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patientsAnneke T Schroen
Department of Surgery, University of Virginia, Charlottesville, VA 22908 0709, USA
J Clin Oncol 23:7074-80. 2005..Treatment access underlies quality cancer care. We hypothesize that mastectomy rates in a rural state are independently influenced by distance to radiation therapy (XRT) and by changing XRT access through opening new facilities... - Immunotherapy for melanomaChristina J Kim
Department of Surgery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Cancer Control 9:22-30. 2002..Preclinical studies and initial clinical trials have shown promising results. Additional clinical trials are currently ongoing to evaluate the clinical efficacy and the associated toxicities of these novel treatment strategies... - Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytesKevin T Hogan
Department of Surgery, University of Virginia, Box 801359, Charlottesville, VA 22908, USA
Immunol Lett 90:131-5. 2003..The peptide may also be useful as a research tool for evaluating spontaneous anti-tumor immune responses in patients with melanoma... - Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cellsChien-Chung Chang
Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
J Biol Chem 281:18763-73. 2006.... - Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell linesV Anne Westbrook
Department of Cell Biology, Center for Research in Contraceptive and Reproductive Health, University of Virginia, Charlottesville, Virginia, USA
Clin Cancer Res 10:101-12. 2004..CONCLUSIONS: The data herein suggest that the SPAN-X protein may be a useful target in cancer immunotherapy... - Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccineElizabeth M H Woodson
Department of Surgery/Division of Surgical Oncology, University of Virginia, Charlottesville, Virginia 22908, USA
J Immunother (1997) 27:380-8. 2004..The hematologic effects of this therapy were delayed in time between the two treatment groups, without dramatic differences in magnitude, which suggests minimal modulation of the IL-2 toxicity by components of the vaccine... - Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family membersKevin T Hogan
Department of Surgery, University of Virginia, Box 801359, Charlottesville, VA 22908, USA
Cancer Immunol Immunother 54:359-71. 2005.... - CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III diseaseIrene M Mullins
Department of Health Evaluation Sciences, University of Virginia Health System, Charlottesville, Virginia 22908-1360, USA
Cancer Res 64:7697-701. 2004..These findings support the hypothesis that the host immune system affects cancer progression and control, and that measures of CCR status of circulating lymphocytes may have prognostic value... - Competition among peptides in melanoma vaccines for binding to MHC moleculesLee W Thompson
Department of Surgery, Division of Surgical Oncology, University of Virginia Health System, Charlottesville, Virginia, USA
J Immunother (1997) 27:425-31. 2004..These data suggest that CTLs can respond to multiple peptides presented on the same antigen-presenting cells and justify further investigation, in clinical trials, of multiple-peptide cancer vaccines... - Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanomaKevin T Hogan
Department of Surgery, University of Virginia, and Argonex, Inc, Charlottesville, Virginia, USA
Cancer Res 64:1157-63. 2004..The properties of the TAG antigens indicate that they are excellent vaccine candidates for the treatment of melanoma and perhaps other cancers... - MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanomaKimberly A Chianese-Bullock
Department of Surgery/Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
J Immunol 174:3080-6. 2005..Cancer-testis Ags are expressed in multiple types of cancer; thus the MAGE-A1(96-104) and MAGE-A10(254-262) peptides may be considered for inclusion in vaccines against cancers of other histologic types, in addition to melanoma... - Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patientsWilliam Chad Cragun
School of Medicine, University of Virginia Health System, Charlottesville, VA, USA
Cancer Immunol Immunother 54:1095-105. 2005..For future vaccine therapies targeting cytotoxic T-cell responses, delaying IL-2 until after initiation of immune responses may be more effective... - Sequential immune escape and shifting of T cell responses in a long-term survivor of melanomaGalina V Yamshchikov
Department of Surgery, University of Virginia, Charlottesville, 22908, USA
J Immunol 174:6863-71. 2005.... - Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2Kimberly A Chianese-Bullock
Department of Surgery/Division of Surgical Oncology, University of Virginia, Charlottesville, Virginia 22908, USA
J Immunother (1997) 28:412-9. 2005..However, careful monitoring for autoimmune toxicities should be incorporated in future clinical studies incorporating low-dose IL-2... - Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2Kerrington R Molhoek
Department of Surgery, Division of Surgical Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
Cancer Res 68:4392-7. 2008.... - Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenaseDavid H Munn
Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
Science 297:1867-70. 2002..IDO+ DCs could also be readily detected in vivo, which suggests that these cells may represent a regulatory subset of APCs in humans... - Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signalingJonathan T Huntington
Norris Cotton Cancer Center, Departments of Physiology, Medicine, and Biochemistry, Dartmouth Medical School, Lebanon NH 03756, USA
J Biol Chem 279:33168-76. 2004..Thus, constitutive activation of this MAPK pathway not only promotes the increased proliferation of melanoma cells but is also important for the acquisition of an invasive phenotype... - Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Clin Cancer Res 12:2291s-2296s. 2006....
Research Grants
- Targeted Molecular Therapeutics for Melanoma: CCI-779 and BevacizumabCraig Slingluff; Fiscal Year: 2007..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. ..
- Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk MelanomaCraig Slingluff; Fiscal Year: 2007....
- MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLSCraig Slingluff; Fiscal Year: 2009....
- MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDESCRAIG LEE SLINGLUFF; Fiscal Year: 2010....
- Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk MelanomaCRAIG LEE SLINGLUFF; Fiscal Year: 2010....
- MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLSCraig Slingluff; Fiscal Year: 2007....
- HLA-A2 ASSOCIATED PEPTIDE EPITOPES FOR CTL ON MELANOMACraig Slingluff; Fiscal Year: 1999....
- MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSFCraig Slingluff; Fiscal Year: 2004..abstract_text> ..
- VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDESCraig Slingluff; Fiscal Year: 2004....
- MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDESCraig Slingluff; Fiscal Year: 2006..The work proposed in this application will set the stage for randomized trials comparing optimized peptide vaccines to optimized vaccines of other types. ..
- MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDESCraig Slingluff; Fiscal Year: 2009....